Actively Recruiting

All Genders
NCT06745830

Lymph Node Pathologic Grading Strategy

Led by Fudan University · Updated on 2024-12-20

2998

Participants Needed

1

Research Sites

53 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The percentage of high-grade patterns in metastatic LNs (mLNs) that can predict poor outcomes has yet to be determined. Additionally, the potential implications of other histologic patterns in metastatic lymph nodes on patient outcomes warrant further investigation. We conducted a retrospective cohort study to investigate the prognostic value of pathologic pattern in metastatic lymph nodes.

CONDITIONS

Official Title

Lymph Node Pathologic Grading Strategy

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with invasive lung adenocarcinoma who underwent surgical resection at Fudan University Shanghai Cancer Center between January 2011 and September 2021
Not Eligible

You will not qualify if you...

  • Adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive mucinous adenocarcinoma, and other adenocarcinoma variants
  • Incomplete data on common driver mutations
  • Unavailable pathologic slides

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 200032

Actively Recruiting

Loading map...

Research Team

Z

Zhu

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here